CL2004000545A1 - Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul - Google Patents

Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Info

Publication number
CL2004000545A1
CL2004000545A1 CL200400545A CL2004000545A CL2004000545A1 CL 2004000545 A1 CL2004000545 A1 CL 2004000545A1 CL 200400545 A CL200400545 A CL 200400545A CL 2004000545 A CL2004000545 A CL 2004000545A CL 2004000545 A1 CL2004000545 A1 CL 2004000545A1
Authority
CL
Chile
Prior art keywords
antagonist
profilaxis
endotheline
hypertension
pathological condition
Prior art date
Application number
CL200400545A
Other languages
English (en)
Inventor
G Mcmahon Amy E Rudolph Ellen
Original Assignee
Pharmacia Corp Sa Organizada B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp Sa Organizada B filed Critical Pharmacia Corp Sa Organizada B
Publication of CL2004000545A1 publication Critical patent/CL2004000545A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UNA COMBINACION DE UNO O MAS ANTAGONISTAS DE RECEPTORES DE LA ALDOSTERONA Y UNO O MAS ANTAGONISTAS DE RECEPTORES DE LA ENDOTELINA Y/O INHIBIDORES DE LA ECE SELECCIONADOS DE UN GRUPO ESPECIFICO DE COMPUESTOS QUE SE DESCRIBEN EN EL PRESENTE DOCUMENTO PARA EL TRATAMIENTO TERAPEUTICO Y/O PROFILAXIS PARA UNA CONDICION DE HIPERTENSION, ENFERMEDAD CARDIOVASCULAR, DISFUNCION RENAL, EDEMA, ENFERMEDAD CEREBROVASCULAR, O CONDICION PATOLOGICA DE INSULINOPATIA.
CL200400545A 2003-03-18 2004-03-17 Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul CL2004000545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45558003P 2003-03-18 2003-03-18

Publications (1)

Publication Number Publication Date
CL2004000545A1 true CL2004000545A1 (es) 2005-01-28

Family

ID=33030025

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400545A CL2004000545A1 (es) 2003-03-18 2004-03-17 Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Country Status (4)

Country Link
US (1) US20040186083A1 (es)
CL (1) CL2004000545A1 (es)
TW (1) TW200503730A (es)
WO (1) WO2004082637A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232813B2 (en) 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
PL1706121T3 (pl) * 2004-01-12 2009-02-27 Turski Lechoslaw Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
WO2006063048A2 (en) 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
WO2006085815A1 (en) * 2005-02-11 2006-08-17 Astrazeneca Ab Thiazole derivatives, their process for their preparation and their use in therapy
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
DE602006013792D1 (de) * 2005-02-18 2010-06-02 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
BRPI0708879A2 (pt) * 2006-03-13 2011-06-14 Encysive Pharmaceuticals peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
CA2655144A1 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
US8080549B2 (en) 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
PL2131841T3 (pl) * 2007-01-30 2013-03-29 Avigen Inc Sposoby leczenia bólu ostrego
US20080287402A1 (en) * 2007-05-03 2008-11-20 Johnson Kirk W Use of a glial attenuator to prevent amplified pain responses caused by glial priming
US20090012012A1 (en) * 2007-07-05 2009-01-08 Jerome Cantor Intratracheal administration of endothelin-suppressing agents for the treatment of respiratory disorders
CA2697057A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
DE102011015142A1 (de) * 2011-03-17 2012-09-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum Agens zur Prophylaxe und Behandlung altersassoziierter Krankheiten und Störungen sowie zur Verlängerung der Lebensdauer
WO2014028059A1 (en) * 2012-08-17 2014-02-20 Father Flanagan's Boys Home Doing Business As Boys Town National Research Hospital Rac1 inhibitors for the treatment of alport glomerular disease
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
US9855245B2 (en) * 2013-04-30 2018-01-02 Abbvie Inc. Methods for improving lipid profiles using atrasentan
WO2017185142A1 (en) * 2016-04-29 2017-11-02 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating atrial fibrillation
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
WO2020257636A1 (en) 2019-06-21 2020-12-24 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Neutralizing antibodies to human endothelin
WO2023150702A2 (en) * 2022-02-03 2023-08-10 The Johns Hopkins University Compositions and methods for treatment of connective tissue disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
CN1142793C (zh) * 1995-06-07 2004-03-24 G·D·瑟尔公司 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists

Also Published As

Publication number Publication date
US20040186083A1 (en) 2004-09-23
TW200503730A (en) 2005-02-01
WO2004082637A3 (en) 2007-05-10
WO2004082637A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
UY28871A1 (es) Antagonistas del receptor de acetilcolina muscarinico
EA200702617A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
UY28598A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
TNSN07264A1 (en) Organic compounds
WO2004100871A3 (en) Combination of an aldosterone receptor antagonist and a renin inhibitor
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
CY2015029I1 (el) Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
CL2004000544A1 (es) Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
AR065083A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
CL2004000449A1 (es) Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
UY28417A1 (es) Antagonistas de los receptores muscarinicos de la acetilcolina
UY28646A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
UY28645A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
CL2007003198A1 (es) Compuestos diarilicos opcionalmente nitrogenados, antagonistas de los receptores opioides; composicion farmaceutica; y uso en el tratamiento de la obesidad.
DK1313485T3 (da) Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
CL2007003613A1 (es) Compuestos nitroderivados, antagonistas del receptor de angiotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension.
UY28567A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
CL2004001507A1 (es) Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.
WO2007033140A3 (en) Prok2 antagonists and methods of use
BRPI0412255A (pt) tratamento da disfunção sexual masculina
UY28415A1 (es) Antagonistas de los receptores muscarinicos de la acetilcolina